265 related articles for article (PubMed ID: 12907598)
1. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
3. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest.
Dhillon NK; Mudryj M
Oncogene; 2002 Jul; 21(30):4626-34. PubMed ID: 12096339
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
Cariou S; Donovan JC; Flanagan WM; Milic A; Bhattacharya N; Slingerland JM
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9042-6. PubMed ID: 10908655
[TBL] [Abstract][Full Text] [Related]
5. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
7. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.
Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV
Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling.
Varma H; Conrad SE
Cancer Res; 2002 Jul; 62(14):3985-91. PubMed ID: 12124331
[TBL] [Abstract][Full Text] [Related]
9. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants for the tissue specificity of SERMs.
Shang Y; Brown M
Science; 2002 Mar; 295(5564):2465-8. PubMed ID: 11923541
[TBL] [Abstract][Full Text] [Related]
12. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
13. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
14. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells.
Buck MB; Pfizenmaier K; Knabbe C
Mol Endocrinol; 2004 Jul; 18(7):1643-57. PubMed ID: 15056732
[TBL] [Abstract][Full Text] [Related]
16. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
Brandi G; Paiardini M; Cervasi B; Fiorucci C; Filippone P; De Marco C; Zaffaroni N; Magnani M
Cancer Res; 2003 Jul; 63(14):4028-36. PubMed ID: 12874002
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7.
Chiarenza A; Lazarovici P; Lempereur L; Cantarella G; Bianchi A; Bernardini R
Cancer Res; 2001 Apr; 61(7):3002-8. PubMed ID: 11306479
[TBL] [Abstract][Full Text] [Related]
18. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
Hui R; Finney GL; Carroll JS; Lee CS; Musgrove EA; Sutherland RL
Cancer Res; 2002 Dec; 62(23):6916-23. PubMed ID: 12460907
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells.
Hong W; Chen L; Li J; Yao Z
Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620
[TBL] [Abstract][Full Text] [Related]
20. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
